Product manufactured by Janssen Biotech, Inc.

Application Nr Approved Date Route Status External Links
BLA103575 None Intravenous None Google , Wikipedia , PubMed , DailyMed , Raw OpenFDA , ECHA , ToxNet , JECFA , FAO , 21 CFR

Indications and Purposes

Indications And Usage: Abciximab Is Indicated As An Adjunct To Percutaneous Coronary Intervention For The Prevention Of Cardiac Ischemic Complications In Patients Undergoing Percutaneous Coronary Intervention In Patients With Unstable Angina Not Responding To Conventional Medical Therapy When Percutaneous Coronary Intervention Is Planned Within 24 Hours Safety And Efficacy Of Abciximab Use In Patients Not Undergoing Percutaneous Coronary Intervention Have Not Been Established. Abciximab Is Intended For Use With Aspirin And Heparin And Has Been Studied Only In That Setting, As Described In Clinical Studies.

All Formulated Excipients (0 Total)


Active Ingredients ( 1 Total)

Name Structure ZINC ID(s)
1. Abciximab